Recent Finacing
Recent Raise
CaroGen develops a vaccine platform using replication‑proficient virus‑like vesicles (rVLVs) that amplify antigen expression to elicit targeted immune responses, initially focused on chronic hepatitis B; licensed from Yale.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor